HPA003890

antibody from Atlas Antibodies

Targeting: ADAR ADAR1, G1P1, IFI4

Provider product page for HPA003890

Western blot

Immunocytochemistry

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [12]
Comments [0]
Validations
Western blot [2]
Immunocytochemistry [1]
Immunohistochemistry [1]

Submit

Product number: HPA003890 - Provider product page
Provider: Atlas Antibodies
Proper citation: Atlas Antibodies Cat#HPA003890, RRID:AB_1078103
Product name: Anti-ADAR
Antibody type: Polyclonal
Description: Polyclonal Antibody against Human ADAR, Gene description: adenosine deaminase, RNA-specific, Alternative Gene Names: ADAR1, G1P1, IFI4, Validated applications: WB, IHC, ICC, Uniprot ID: P55265, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Reactivity: Human
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 100 µl
Concentration: 0.1 mg/ml
Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Handling: The antibody solution should be gently mixed before use.

ADAR protein structure - HPA003890 shown in red.

Submitted references ADAR1 promotes cisplatin resistance in intrahepatic cholangiocarcinoma by regulating BRCA2 expression through A‐to‐I editing manner

Liu Q, Huang C, Chen S, Zhu Y, Huang X, Zhao G, Xu Q, Shi Y, Li W, Wang R, Yin X
Cell Proliferation 2024;57(10)

Extracellular vesicle‑mediated RNA editing may underlie the heterogeneity and spread of hepatocellular carcinoma in human tissue and in vitro

Shibata C, Otsuka M, Shimizu T, Seimiya T, Kishikawa T, Aoki T, Fujishiro M
Oncology Reports 2023;50(5)

ADAR1 downregulation by autophagy drives senescence independently of RNA editing by enhancing p16INK4a levels

Hao X, Shiromoto Y, Sakurai M, Towers M, Zhang Q, Wu S, Havas A, Wang L, Berger S, Adams P, Tian B, Nishikura K, Kossenkov A, Liu P, Zhang R
Nature Cell Biology 2022;24(8):1202-1210

Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironment

Hariharan A, Qi W, Rehrauer H, Wu L, Ronner M, Wipplinger M, Kresoja‐Rakic J, Sun S, Oton‐Gonzalez L, Sculco M, Serre‐Beinier V, Meiller C, Blanquart C, Fonteneau J, Vrugt B, Rüschoff J, Opitz I, Jean D, de Perrot M, Felley‐Bosco E
Molecular Oncology 2022;16(22):3949-3974

Double-Stranded RNA Structural Elements Holding the Key to Translational Regulation in Cancer: The Case of Editing in RNA-Binding Motif Protein 8A

Abukar A, Wipplinger M, Hariharan A, Sun S, Ronner M, Sculco M, Okonska A, Kresoja-Rakic J, Rehrauer H, Qi W, Beusechem V, Felley-Bosco E
Cells 2021;10(12):3543

How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations

Rehrauer H, Wu L, Blum W, Pecze L, Henzi T, Serre-Beinier V, Aquino C, Vrugt B, de Perrot M, Schwaller B, Felley-Bosco E
Oncogene 2018;37(20):2645-2659

Decreased A-to-I RNA editing as a source of keratinocytes' dsRNA in psoriasis

Shallev L, Kopel E, Feiglin A, Leichner G, Avni D, Sidi Y, Eisenberg E, Barzilai A, Levanon E, Greenberger S
RNA 2018;24(6):828-840

ADAR1 deletion induces NFκB and interferon signaling dependent liver inflammation and fibrosis

Ben-Shoshan S, Kagan P, Sultan M, Barabash Z, Dor C, Jacob-Hirsch J, Harmelin A, Pappo O, Marcu-Malina V, Ben-Ari Z, Amariglio N, Rechavi G, Goldstein I, Safran M
RNA Biology 2016;14(5):587-602

A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme

Galore-Haskel G, Nemlich Y, Greenberg E, Ashkenazi S, Hakim M, Itzhaki O, Shoshani N, Shapira-Fromer R, Ben-Ami E, Ofek E, Anafi L, Besser M, Schachter J, Markel G
Oncotarget 2015;6(30):28999-29015

MicroRNA Editing Facilitates Immune Elimination of HCMV Infected Cells

Gao S, Nachmani D, Zimmermann A, Oiknine Djian E, Weisblum Y, Livneh Y, Khanh Le V, Galun E, Horejsi V, Isakov O, Shomron N, Wolf D, Hengel H, Mandelboim O
PLoS Pathogens 2014;10(2):e1003963

Witman N, Behm M, Öhman M, Morrison J
Stem Cells and Development 2013;22(16):2254-2267

Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature

Rice G, Kasher P, Forte G, Mannion N, Greenwood S, Szynkiewicz M, Dickerson J, Bhaskar S, Zampini M, Briggs T, Jenkinson E, Bacino C, Battini R, Bertini E, Brogan P, Brueton L, Carpanelli M, De Laet C, de Lonlay P, del Toro M, Desguerre I, Fazzi E, Garcia-Cazorla À, Heiberg A, Kawaguchi M, Kumar R, Lin J, Lourenco C, Male A, Marques W, Mignot C, Olivieri I, Orcesi S, Prabhakar P, Rasmussen M, Robinson R, Rozenberg F, Schmidt J, Steindl K, Tan T, van der Merwe W, Vanderver A, Vassallo G, Wakeling E, Wassmer E, Whittaker E, Livingston J, Lebon P, Suzuki T, McLaughlin P, Keegan L, O'Connell M, Lovell S, Crow Y
Nature Genetics 2012;44(11):1243-1248

No comments: Submit comment

Enhanced validation

Submitted by: klas2
Enhanced method: Genetic validation
Main image
Experimental details: Western blot of cell lysate from U-2 OS cells transfected with either siRNA targeting ADAR or control siRNA. Lane 1: Marker (250, 130, 95, 72, 55, 36, 28, 17, 10) Lane 2: Cell lysate from U-2OS cells transfected with siRNA targeting ADAR Lane 3: N/A Lane 4: Cell lysate from U-2OS cells transfected with control siRNA Right image, lane 1-4: loading control
Sample type: U-2 OS
Primary Ab dilution: 1:196
Conjugate: Horseradish Peroxidase
Secondary Ab: Secondary Ab
Secondary Ab dilution: 1:3000
Knockdown/Genetic Approaches Application: Western blot
KD Reagent Type: siRNA
Downregulation: >75%
KD Reagent Provider: Thermo Fisher Scientific
KD Reagent Prod page: KD Reagent Prod page
KD Reagent Prod no: s1007
KD Reagent Page 2: KD Reagent Page 2
KD Reagent Prod no 2: s1008
KD Reagent Page 3: KD Reagent Page 3
KD Reagent Prod no 3: s1009
Antibody Lot Number: R04101
Appendix: 565c9c16e5d38.pdf

: Show more

Enhanced validation

Submitted by: Atlas Antibodies (provider)
Enhanced method: Genetic validation
Main image
Experimental details: Western blot analysis in U-251MG cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-ADAR antibody. Remaining relative intensity is presented. Loading control: Anti-GAPDH.
Sample type: Human
Protocol: Protocol

Supportive validation

Submitted by: Atlas Antibodies (provider)
Main image
Experimental details: Immunofluorescent staining of human cell line U-251 MG shows localization to nucleoplasm & nucleoli.
Sample type: Human

Supportive validation

Submitted by: Atlas Antibodies (provider)
Enhanced method: Orthogonal validation
Main image
Experimental details: Immunohistochemistry analysis in human testis and skeletal muscle tissues using HPA003890 antibody. Corresponding ADAR RNA-seq data are presented for the same tissues.
Sample type: Human
Protocol: Protocol
Orthogonal method: Orthogonal validation of protein expression using IHC by comparison to RNA-seq data of corresponding target in high and low expression tissues.

: Show more